QCLS Stock — Q/C Technologies Inc.: Cash, EV, Pipeline

Share price

$0.76

Market cap

$6.3M

Cash

$11.0M

Enterprise value

-$4.7M

Balance sheet

Cash	$11.0M
Debt	$0.0M
Net cash	$11.0M
Enterprise value	-$4.7M
Basic shares	8.2M shares
Fully diluted shares	8.9M shares
Fully diluted market cap	$6.7M
Cash per share	$1.34

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading QCLS daily closes…

Loading price history…

Pipeline assets

Isomyosamine

Phase 2 · Active Modality: small molecule (oral)

Aliases MYMD-1

Target TNF-α

Indications

not disclosed (Phase 2)

Status note Oral next-generation TNF-α inhibitor; Phase 2b study suspended (development costs fell sharply in 2026). Company resources redirected to laser-based and optical computing (qc-LPU100/LPU); evaluating strategic alternatives for the legacy pharmaceutical programs including divestiture, partnering or licensing.

Supera-CBD

Stage not disclosed · Active

Indications

not disclosed (Stage not disclosed)

Status note Legacy pharmaceutical product candidate alongside Isomyosamine; no stage, target or indication stated in excerpts. Company is a party to manufacture/formulation agreements for Supera-CBD and MIRA1a; evaluating strategic alternatives for legacy programs.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	50,000	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

QCLS — Q/C Technologies Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders